scholarly journals Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy

Hepatology ◽  
2013 ◽  
Vol 57 (6) ◽  
pp. 2448-2457 ◽  
Author(s):  
Wim Laleman ◽  
Macarena Simon-Talero ◽  
Geert Maleux ◽  
Mercedes Perez ◽  
Koen Ameloot ◽  
...  
2016 ◽  
Vol 22 (6) ◽  
pp. 723-731 ◽  
Author(s):  
Amanda M. Lynn ◽  
Siddharth Singh ◽  
Stephen E. Congly ◽  
Disha Khemani ◽  
David H. Johnson ◽  
...  

2016 ◽  
Vol 22 (12) ◽  
pp. 1734-1735 ◽  
Author(s):  
Amir Kashani ◽  
H. G. Lipshutz ◽  
Andrew S. Klein ◽  
Irene Kim ◽  
Marc L. Friedman ◽  
...  

2019 ◽  
Vol Volume 11 ◽  
pp. 23-34 ◽  
Author(s):  
Cyriac Abby Philips ◽  
Sasidharan Rajesh ◽  
Philip Augustine ◽  
Guruprasad Padsalgi ◽  
Rizwan Ahamed

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Jonathan K. Park ◽  
Sung-Ki Cho ◽  
Stephen Kee ◽  
Edward W. Lee

While balloon-assisted retrograde transvenous obliteration (BRTO) has been used for two decades in Asia for the management of gastric variceal bleeding, it is still an emerging therapy elsewhere. Given the shunt closure brought about by the procedure, BRTO has also been used for the management of portosystemic encephalopathy with promising results. Modified versions of BRTO have been developed, including plug-assisted retrograde transvenous obliteration (PARTO), where a vascular plug is deployed within a portosystemic shunt. To our knowledge, we present the first North American case of PARTO in the setting of a large splenorenal shunt for the management of portosystemic encephalopathy.


2020 ◽  
Vol 72 (6) ◽  
pp. 1140-1150 ◽  
Author(s):  
Michael Praktiknjo ◽  
Macarena Simón-Talero ◽  
Julia Römer ◽  
Davide Roccarina ◽  
Javier Martínez ◽  
...  

2020 ◽  
Vol 04 (02) ◽  
pp. 148-156
Author(s):  
David S. Shin ◽  
Hong Vo ◽  
Guy Johnson ◽  
Raimund Pichler ◽  
Scott W. Biggins

AbstractCirrhosis with complications of portal hypertension portends a poor prognosis. Transjugular intrahepatic portosystemic shunts (TIPS) can successfully treat some of these complications in select patients. While the safety and efficacy of TIPS have improved significantly over the past decade, certain patients are categorized as high-risk based on various demographic, laboratory, and comorbid factors. Herein, we provide an in-depth review of TIPS in these settings, including high model for end-stage liver disease score, hepatic malignancy, advanced age, cardiac disease, renal dysfunction, and pregnancy, and discuss their impact on patient selection and procedural considerations.


2020 ◽  
Vol 13 ◽  
pp. 175628482096128 ◽  
Author(s):  
Judit Vidal-González ◽  
Sergi Quiroga ◽  
Macarena Simón-Talero ◽  
Joan Genescà

Portal hypertension is the main consequence of liver cirrhosis, leading to severe complications such as variceal hemorrhage, ascites or hepatic encephalopathy. As an attempt to decompress the portal venous system, portal flow is derived into the systemic venous system through spontaneous portosystemic shunts (SPSSs), bypassing the liver. In this review, we aim to provide an overview of the published reports in relation to the prevalence and physiopathology behind the appearance of SPSS in liver cirrhosis, as well as the complications derived from its formation and its management. The role of SPSS embolization is specifically discussed, as SPSSs have been assessed as a therapeutic target, mainly for patients with recurrent/persistent hepatic encephalopathy and preserved liver function. Furthermore, different aspects of the role of SPSS in liver transplantation, as well as in candidates for transjugular intrahepatic portosystemic shunt are reviewed. In these settings, SPSS occlusion has been proposed to minimize possible deleterious effects, but results are so far inconclusive.


Sign in / Sign up

Export Citation Format

Share Document